Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15years after the introduction of universal Hib vaccination related to notifications of invasive disease

APMIS

Volumn 118, Issue 11, 2010, Pages 878-887

  Hallander, Hans O ^a   Lepp, Tiia ^a   Ljungman, Margaretha ^a   Netterlid, Eva ^a   Andersson, Mikael ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

ELISA IgG anti Hib; Haemophilus influenzae; Notifications; Seroepidemiology; Vaccination

Indexed keywords

ACT HIB; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; PENTAVAC; POLYRIBOSYL RIBITOL PHOSPHATE; POLYRIBOSYL RIBITOL PHOSPHATE ANTIBODY; UNCLASSIFIED DRUG; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE; HAEMOPHILUS VACCINE; VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL IMMUNITY; CHILD; DIPHTHERIA; ENVIRONMENTAL EXPOSURE; GROUPS BY AGE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; MAJOR CLINICAL STUDY; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROPREVALENCE; SWEDEN; TETANUS; VACCINATION; ADOLESCENT; BACTERIAL MEMBRANE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; HAEMOPHILUS INFLUENZAE; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; STANDARD;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; SWEDEN; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 78149235886     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02674.x     Document Type: Article

References (30)

1. Moxon ER. Bacterial variation, virulence and vaccines. Microbiology 2009;155:997-1003.
2. Ulanova M, Tsang RS. Invasive Haemophilus influenzae disease: changing epidemiology and host-parasite interactions in the 21st century. Infect Genet Evol 2009;9:594-605.
3. Chandran A, Watt JP, Santosham M. Prevention of Haemophilus influenzae type b disease: past success and future challenges. Expert Rev Vaccines 2005;4:819-27.
4. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302-17.
5. Garpenholt O, Silfverdal SA, Hugosson S, Fredlund H, Bodin L, Romanus V, et al. The impact of Haemophilus influenzae type b vaccination in Sweden. Scand J Infect Dis 1996;28:165-9.
6. Carlsson RM, Gustafsson L. Ten year report. Pertussis surveillance in Sweden. Progress Report No. 4, 1 October - 31 December 1997. Solna: Smittskyddsinstitutet, 2008. Available online at
7. Farhoudi D, Lofdahl M, Giesecke J. Invasive Haemophilus influenzae type b disease in Sweden 1997-2003: epidemiological trends and patterns in the post-vaccine era. Scand J Infect Dis 2005;37:717-22.
8. Heath PT, Bowen-Morris J, Griffiths D, Griffiths H, Crook DW, Moxon ER. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997;77:488-92.
9. Ladhani S, Heath PT, Ramsay ME, Slack MP, Kibwana E, Pollard AJ, et al. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 2009;49:372-80.
10. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003;361:1521-3.
11. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984;149:1034-5.
12. Kayhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994;22:397-402.
13. Makela PH, Kayhty H, Leino T, Auranen K, Peltola H, Ekstrom N, et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003;22:287-92.
14. Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984;310:1561-6.
15. Takala AK, Eskola J, Leinonen M, Kayhty H, Nissinen A, Pekkanen E, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991;164:982-6.
16. Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10years after the introduction of a universal childhood pertussis vaccination program. APMIS 2009;117:912-22.
17. Olin P, Carlsson RM, Johansen K, Hallander HO, Ljungman M, Svensson Å et al. Vaccinationsuppföljning, Seroepidemiologisk tvärsnittsstudie 1997, Slutrapport. SMI:s rapportserie. Solna: Smittskyddsinstitutet, 2004. Available online at
18. Hallander HO. Microbiological and serological diagnosis of pertussis. Clin Infect Dis 1999; 28(Suppl. 2):S99-106.
19. Reizenstein E, Hallander HO, Blackwelder WC, Kuhn I, Ljungman M, Mollby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 1995;183:279-90.
20. De Melker HE, Van Den Hof S, Berbers GA, Conyn-van Spaendonck MA. Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. Vaccine 2003;21:716-20.
21. Scheifele DW, Halperin SA, Guasparini R, Meekison W, Pim C, Barreto L. Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. J Pediatr 1999;135:240-5.
22. Hallander HO, Ljungman M, Storsaeter J, Gustafsson L. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS 2009;117:797-807.
23. Tiru M, Hallander HO, Gustafsson L, Storsaeter J, Olin P. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 2000;18:2295-306.
24. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 1998; 177:1758-61.
25. Insel RA, Anderson PW Jr. Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B. J Immunol 1982;128:1267-70.
26. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 1998;4:229-37.
27. Scheifele DW. Recent trends in pediatric Haemophilus influenzae type B infections in Canada. Immunization Monitoring Program, Active (IMPACT) of the Canadian Paediatric Society and the Laboratory Centre for Disease Control. CMAJ 1996;154:1041-7.
28. Oh SY, Griffiths D, John T, Lee YC, Yu LM, McCarthy N, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008;197:1275-81.
29. Schouls L, Van Der Heide H, Witteveen S, Zomer B, Van Der Ende A, Burger M, et al. Two variants among Haemophilus influenzae serotype b strains with distinct bcs4, hcsA and hcsB genes display differences in expression of the polysaccharide capsule. BMC Microbiol 2008;8:35-46.
30. Cerquetti M, Cardines R, Ciofi Degli Atti ML, Giufre M, Bella A, Sofia T, et al. Presence of multiple copies of the capsulation b locus in invasive Haemophilus influenzae type b (Hib) strains isolated from children with Hib conjugate vaccine failure. J Infect Dis 2005;192:819-23.